Ajulemic acid

Drug Profile

Ajulemic acid

Alternative Names: CPL-7075; CT-3; DMH-11C; HU-239; IP-751; JBT-101; Resunab

Latest Information Update: 30 Dec 2016

Price : $50

At a glance

  • Originator University of Massachusetts Medical School
  • Developer Cervelo Pharmaceuticals; Corbus Pharmaceuticals; Indevus Pharmaceuticals; National Institute of Arthritis and Musculoskeletal and Skin Diseases; University of Erlangen-Nuremberg; University of Pennsylvania; University of Siena
  • Class Anti-inflammatories; Antiasthmatics; Antirheumatics; Cannabinoids; Non-opioid analgesics; Small molecules
  • Mechanism of Action Cannabinoid receptor CB2 agonists; Interleukin 1 beta inhibitors; Matrix metalloproteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis; Systemic scleroderma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Cystic fibrosis; Systemic scleroderma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Interstitial cystitis

Highest Development Phases

  • Phase II Cystic fibrosis; Dermatomyositis; Systemic scleroderma
  • Phase I Inflammation
  • Preclinical Pulmonary fibrosis
  • Discontinued Interstitial cystitis; Muscle spasticity; Neuropathic pain; Pain; Poisoning

Most Recent Events

  • 29 Dec 2016 Corbus Pharmaceuticals Holdings completes a phase II trial for Cystic Fibrosis in USA, Belgium, France, Germany, Italy, Poland and the UK
  • 29 Nov 2016 Corbus Pharmaceuticals initiates a phase II open-label extension study for Dermatomyositis in USA
  • 14 Nov 2016 Positive topline efficacy and adverse events data from a phase II trial in Scleroderma released by Corbus Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top